Oragenics, Inc.
Oragenics, Inc. (OGEN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ogen · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Oragenics, Inc. (OGEN) measures how much investors pay for each dollar of the company's trailing earnings. OGEN's current PE ratio of N/A is calculated by dividing its stock price of $0.61 by its TTM earnings per share of -$2.28.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Oragenics, Inc.You OGEN | $3M | N/A | — | -$2.28 |
 AIM ImmunoTech Inc. AIM | $2M | N/A | — | -$8.62 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 Ensysce Biosciences, Inc. ENSC | $2M | N/A | — | -$3.98 |
 KALA BIO, Inc. KALA | $50M | N/A | — | -$3.31 |
 Kazia Therapeutics Limited KZIA | $18M | N/A | — | -$18.90 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.56 | — | |
2024-12-31 FY2024 | — | $-1.60 | — | |
2023-12-31 FY2023 | — | $-9.18 | — | |
2022-12-31 FY2022 | — | $-7.11 | — | |
2021-12-31 FY2021 | — | $-8.35 | — | |
2020-12-31 FY2020 | — | $-28.05 | — | |
2019-12-31 FY2019 | — | $-22.10 | — | |
2018-12-31 FY2018 | — | $-45.62 | — | |
2017-12-31 FY2017 | — | $-81.99 | — | |
2016-12-31 FY2016 | — | $-94.35 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Oragenics, Inc. (OGEN) measures how much investors pay for each dollar of the company's trailing earnings. OGEN's current PE ratio of N/A is calculated by dividing its stock price of $0.61 by its TTM earnings per share of -$2.28.
Frequently asked questions
OGEN pe ratio · 6 questionsOGEN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.61 and TTM EPS of -$2.28. Data sourced from Financial Modeling Prep via OGEN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Oragenics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08